ARDT Ardent Health Partners, Inc.

Pomerantz LLP is investigating potential securities fraud claims against Ardent Health, Inc. (NYSE: ARDT) after the company announced a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves. This announcement on November 12, 2025, led to a significant drop in Ardent's stock price, falling 33.81% to $9.30 per share the following day. Investors who suffered losses are advised to contact Pomerantz LLP.

Pomerantz LLP has initiated an investigation into Ardent Health, Inc. (NYSE: ARDT) following a significant drop in its stock price. This probe comes after Ardent announced a $43 million revenue reduction due to accounting changes and a $54 million increase in professional liability reserves, leading to a 33.81% stock decline. The law firm is investigating potential securities fraud or unlawful business practices by the company's officers and/or directors.

Pomerantz LLP is investigating potential securities fraud claims against Ardent Health, Inc. (NYSE: ARDT) after the company's stock price fell significantly following its Q3 2025 financial results. Ardent reported a $43 million revenue reduction due to accounting changes and a $54 million increase in professional liability reserves. Investors who suffered losses are encouraged to contact Pomerantz LLP.

Pomerantz LLP is investigating potential securities fraud claims against Ardent Health, Inc. (NYSE: ARDT) after the company announced a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves for Q3 2025. This news caused Ardent's stock price to fall by 33.81% to $9.30 per share on November 13, 2025. Investors are encouraged to contact Pomerantz LLP regarding potential class action involvement.

Ardent Health, Inc. (NYSE:ARDT) has received a consensus "Hold" rating from twelve analysts, with an average 12-month target price of $14.67, despite recent target trims and rating adjustments from several brokers. The company exceeded Q3 earnings expectations and provided FY2025 guidance. Institutional interest in ARDT is on the rise, evidenced by significant increases in holdings by major investors such as Vanguard and Ameriprise.

Pomerantz LLP is investigating Ardent Health, Inc. (NYSE: ARDT) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows Ardent's announcement of a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves, which caused its stock price to fall significantly. Investors who believe they have been affected are encouraged to contact the firm regarding a potential class action lawsuit.